Inverse Association of Fibrates and Liver Cancer: A Population‐Based Case‐Control Study in Taiwan

Abstract

This large‐scale case‐control study in Taiwan elucidated the potential connection between fibrate use and liver cancer by using the Longitudinal Health Insurance Database 2005 with a propensity‐score–matching design. In total, 4173 patients diagnosed as having liver cancer were included as cases, and 4173 propensity‐score–matched patients without liver cancer were identified as controls. The association between previous fibrate use and liver cancer occurrence was demonstrated using conditional logistic regression. Fibrate use was noted in 371 (8.89%) cases and 481 (11.53%) controls. After adjustments, the cases had significantly lower odds of previous fibrate use than did the controls (adjusted odds ratio 0.70, 95%CI 0.60‐0.82); moreover, regardless of the patients’ sex, age group, and comorbidities, the cases were less likely to have used fibrates than were the controls. Dose‐dependent analysis revealed that 1‐695 cumulative defined daily doses of fibrates may significantly induce a protective effect for liver cancer. Although other fibrate dose intervals did not reach statistical significance, the dose‐response curve presented the trend of a protective effect for liver cancer among the fibrate users. In summary, fibrate use had a significant protective effect against liver cancer in this Asian population.

The role of benzodiazepines in common conditions: a narrative review focusing on lormetazepam

“…This is supported by data showing that sleep disorders are worse in patients with inflammatory than non-inflammatory skin disorders (Mostaghimi and Hetzel, 2019). Moreover, etiological factors and consequences, such as symptom severity, fatigue, and anxiety, exacerbate one another to promote a vicious cycle of impaired sleep, dermatological worsening, and psychiatric comorbidities (Thorburn and Riha, 2010;Walia and Mehra, 2016;Kaaz et al, 2019;Li et al, 2019;Misery et al, 2020;Myers et al, 2021).…”

Impact of Antihypertensive, Lipid-Lowering, and Antiplatelet Agents on Development of Hepatocellular Carcinoma in Patients with Fatty Liver Disease and Diabetes

“…Lee et al 24 reported decreased HCC mortality with brate (or statin) use in geriatric patients. Furthermore, Li et al 25 reported that brate use had a signi cant protective effect against liver cancer in Taiwan. The hypothesis that statins and brates, which are primarily metabolized in the liver, exert a protective effect against liver diseases and HCC by directly affecting fat metabolism in a liver burdened with excessive fat is plausible.…”

Metabolic syndrome and thyroid Cancer: risk, prognosis, and mechanism

“…These smaller particles cause direct damage to the blood vessels, and vascular injury accelerates cell invasion and metastasis. Fibrates are often used for the lipid-lowering treatment of patients with high TG levels, and may have protective functions in tumor progression in the breast, gastrointestinal tract, respiratory tract and urinary system [ 42 , 43 ]. However, the aforementioned studies lacked data on whether the patients took drugs, if they did, what drugs they took, and how they took these.…”